Our success has been built upon maintaining long-term relationships with our clients, which encompass the largest players in the pharmaceutical industry, middle pharma, healthcare institutions and biotechs.
We believe in communication, flexibility, trust and quality – and in our client relationships, this yields insights that drive results.
Creativ-Ceutical has been qualified for French Crédit Impôt Recherche (CIR) status - a corporate tax relief measure based on R&D expenses incurred by firms operating in France. This incentive helps to support companies’ R&D efforts and increase their competitiveness.
We are proud to have been selected by the European Commission as preferred vendor for assisting the Executive Agency for Health and Consumers and the Directorate-General for Health and Consumers in carrying out their activities related to health information, providing health reports and health and economic analysis.
Here is what our clients say about us:
“Creativ-Ceutical has helped Air Liquide Santé International to assess new indications for long-known molecule. Hard-workers and based on strict methodology, they have been great consultants and proven highest added value to internal thinking. Large desk research plus clinicians and payers interviews brought solid information and insights to this project. Very useful to help formalize strategic recommendations, they inspire expertise and vision to other projects within Air Liquide as well.”International Medical Director, Air Liquide Santé International World Business Line
“Considering Creativ-Ceutical’s experience in market access for rare disease, we have decided to work with the team. They have provided insightful comments which will help us going throughout all hurdles in this particular therapeutic area. The collaboration is easy and flexibility is very much appreciated.”Senior Vice President, Ipsen, Global Market Access & Pricing
“Creativ-Ceutical brought a high level of expertise and scientific rigor to our first ever NICE STA and the first ever NICE STA in OAB. We really appreciate their huge technical and strategic contribution to this submission and the flexibility they showed during the whole process, often working to extremely short deadlines. A key strength they have demonstrated thorough out all our joint collaborations is the ability to firstly quickly understand our needs and objectives and secondly they have been able to provide adequate direction and solutions as result.” Associate Director, Astellas, Health Economics and Outcomes Research
“The European Commission was very pleased with the work done by Creativ-Ceutical on the project “EU Pharmaceutical expenditure forecast”. The innovative model developed for pharmaceutical expenditure forecast allowed to inform the European Commission on how Member States' public pharmaceutical expenditures are likely to evolve over the next few years, both from medicinal products going off patent and from new patent medicinal products.”EU Commission DG SANCO
“Our collaboration with Creativ-Ceutical started three years ago with a project in the field of opioid dependence. It is an ongoing effort with numerous projects for American, European and Canadian markets. They proved to be a highly professional team that took the best from both academia and business: methodological rigor, scientific curiosity, understanding of the field and ability to meet tight deadlines. A great value added to our business.”Chief Executive Officer, ZRX Outcomes
“While planning and executing the preparation for market entrance of NeuroSearch’s major asset, Creativ Ceutical has been highly instrumental. The support NeuroSearch had in building and evaluating cost/effectiveness models, HEOR programs, value and price evaluations together with related presentation and publication planning was crucial when canvassing this major NeuroSearch project. The way Creativ-Ceutical performed their assignment stimulated internal colleagues as well as external KOLs engaged in the project.”Vice President, NeuroSearch, Market Access & Commercialisation